Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
- G. Norman
- , S. Rice
- , E. Spackman
- , L. Stirk
- , A. Danso-Appiah
- , D. Suh
- , S. Palmer
- , A. Eastwood
- University of York
Research output: Contribution to journal › Review article › peer-review
14
Citations
(Scopus)